|Day's Range||3.87 - 4.01|
|52 Week Range||3.50 - 9.29|
|PE Ratio (TTM)||-8.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TherapeuticsMD (TXMD) warrants investors' attention based on moves in the options market lately.
Following the FDA issuing a complete response letter, or CRL, in response to TherapeuticsMD Inc (NYSE: TXMD )'s NDA for TX-004HR, Oppenheimer downgraded the shares of the company. TX-004HR, or Yuvvexy, ...
Shares are tumbling after news broke that the FDA has rejected its application for Yuvvexy.